Efficacy, Safety and Tolerability of a New 10% Liquid Intravenous Immune Globulin [IGIV 10%] in Patients with Primary Immunodeficiency


The present clinical study was designed to evaluate the efficacy, pharmacokinetics and safety of a new 10% liquid intravenous immune globulin in patients with primary immunodeficiency diseases. Sixty-one adults and children with primary immuno-deficiency diseases received doses of 300–600 mg/kg body weight every 21–28 days for 12 months. No validated acute serious bacterial infections were reported. The 95% confidence interval for the annualized rate of acute serious bacterial infections (primary endpoint) was 0–0.060. A total of four predefined validated other bacterial infections commonly occurring in primary immunodeficiency disease subjects were observed; none were serious, severe or resulted in hospitalization. The median elimination half-life of IgG was 35 days. Median total IgG trough levels varied from 9.6 to 11.2 g/L. Temporally associated adverse experiences were determined for 72 h after each infusion and the most common adverse experience was headache, which was associated with 6.9% of infusions. The study met the primary endpoint for efficacy and demonstrated excellent tolerability of the new 10% liquid intravenous imunoglobulin preparation.

DOI: 10.1007/s10875-006-9025-3

6 Figures and Tables

Citations per Year

1,405 Citations

Semantic Scholar estimates that this publication has 1,405 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Church2006EfficacySA, title={Efficacy, Safety and Tolerability of a New 10% Liquid Intravenous Immune Globulin [IGIV 10%] in Patients with Primary Immunodeficiency}, author={Joseph A . Church and Heinz Leibl and Mark R. Stein and Isaac Melamed and Arye Rubinstein and Lynda C . Schneider and Richard L. Wasserman and Borislava G. Pavlova and Karl Birthistle and Marianne Mancini and Sandor Fritsch and Lisa Patrone and Kerry Moore-Perry and Hartmut J. Ehrlich}, journal={Journal of Clinical Immunology}, year={2006}, volume={26}, pages={388-395} }